Sector News

China’s Fosun pulls back from U.S. biotech scene

May 31, 2019
Life sciences

Fosun is pulling back from the U.S. biotech sector in response to the escalating trade war with China. The Chinese conglomerate has struck deals with Kite Pharma, Revance Therapeutics and other U.S. biotechs in the past but now plans to limit its activities in the country.

Talking to Bloomberg, Kevin Xie, who oversees Fosun’s healthcare investments outside of China, set out how the standoff between government leaders at the two global powers has affected his work.

“Trade friction has impacted our investments in the U.S., but not to the extent of stopping all deals,” Xie said. “Companies in the U.S. still welcome investments and are willing to work with us, so we are making some changes in the wiggle room allowed under the law.”

Fosun’s difficulties stem from a shift in the position of the Committee on Foreign Investment in the United States (CFIUS). Under President Donald Trump, CFIUS has intensified its assessments of the national security implications of the takeovers of domestic assets and extended its reach beyond M&A.

Notably, in August CFIUS gained the power to screen certain foreign venture capital transactions and to restrict the licensing and transfer of technologies. The full impact of the new powers will only become clear as key details about its implementation, such as the technologies the restrictions apply to, are worked out. But the initial impact has been big enough to persuade Fosun to shift focus from the U.S.

If other Chinese investors follow Fosun’s lead, the U.S. biotech sector will lose access to a significant source of investment. Last year, Chinese investors struck U.S. healthcare deals worth $2.8 billion, up from around $700 million the previous year.

The surge in the outbound activity of Chinese investors and biopharma companies has provided U.S. with money and overseas partners. And U.S. VCs have secured money from Fosun and other Chinese players, too.

By Nick Paul Taylor

Source: Fierce Biotech

comments closed

Related News

May 21, 2022

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

Life sciences

A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.

May 21, 2022

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

May 21, 2022

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”